CF
BNTC icon

Cantor Fitzgerald’s Benitec Biopharma BNTC Stock Holding History

Cantor Fitzgerald’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Hold
46,659
– – 0.01% 266
2026
Q1 		$497K Buy
+46,659
New +$540K 0.01% 219
2023
Q2 		– Sell
-1,474
Closed -$5.26K – 581
2023
Q1 		$5.26K Hold
1,474
– – ﹤0.01% 646
2022
Q4 		$4K Sell
1,474
-6,397
-81% -$21.7K ﹤0.01% 676
2022
Q3 		$50K Buy
+7,871
New +$100K ﹤0.01% 654

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Cantor Fitzgerald's BNTC Position: Q2 2026 in Review

Cantor Fitzgerald held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 46,659 shares worth $624K. The position accounts for 0.01% of the portfolio, ranked #266.

Cantor Fitzgerald first reported a position in BNTC in Q3 2022 and has held it in 5 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Cantor Fitzgerald held 46,659 shares of Benitec Biopharma worth $624K as of Q2 2026.
  • Cantor Fitzgerald left its Benitec Biopharma share count unchanged in Q2 2026.
  • Benitec Biopharma made up 0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #266 holding.
  • Cantor Fitzgerald first reported a position in Benitec Biopharma in Q3 2022 and has held it in 5 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.